Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

Fenofibrate is widely used in clinical therapy to effectively ameliorate the development of non-alcoholic fatty liver disease (NAFLD); however, its specific molecular mechanism of action remains largely unknown. MicroRNAs (miRNAs) are key mediators in regulating endoplasmic reticulum (ER) stress dur...

Cijeli opis

Bibliografski detalji
Glavni autori: Dan Zhang, Shanzhuang Niu, Yicheng Ma, Hang Chen, Yu Wen, Mingke Li, Bo Zhou, Yi Deng, Chunjing Shi, Guangyu Pu, Meng Yang, Xianmei Wang, Chenggang Zou, Yuanli Chen, Lanqing Ma
Format: Članak
Jezik:English
Izdano: Frontiers Media S.A. 2022-01-01
Serija:Frontiers in Pharmacology
Teme:
non-alcoholic fatty liver disease
fenofibrate
endoplasmic reticulum stress
let-7
microRNA
sarco/endoplasmic reticulum calcium ATPase
Online pristup:https://www.frontiersin.org/articles/10.3389/fphar.2021.770652/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.770652/full

Slični predmeti